PuSH - Publication Server of Helmholtz Zentrum München

von Mässenhausen, A.* ; Schlecht, M.N.* ; Beer, K.* ; Maremonti, F.* ; Tonnus, W.* ; Belavgeni, A.* ; Gavali, S.* ; Flade, K.* ; Riley, J.S.* ; Zamora Gonzalez, N.* ; Brucker, A.J.* ; Becker, J.N.* ; Tmava, M.* ; Meyer, C.* ; Peitzsch, M.* ; Hugo, C.* ; Gembardt, F.* ; Angeli, J.P.F.* ; Bornstein, S.R. ; Tait, S.W.G.* ; Linkermann, A.*

Treatment with siRNAs is commonly associated with GPX4 up-regulation and target knockdown-independent sensitization to ferroptosis.

Sci. Adv. 10:eadk7329 (2024)
Postprint DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Small interfering RNAs (siRNAs) are widely used in biomedical research and in clinical trials. Here, we demonstrate that siRNA treatment is commonly associated with significant sensitization to ferroptosis, independently of the target protein knockdown. Genetically targeting mitochondrial antiviral-signaling protein (MAVS) reversed the siRNA-mediated sensitizing effect, but no activation of canonical MAVS signaling, which involves phosphorylation of IkBα and interferon regulatory transcription factor 3 (IRF3), was observed. In contrast, MAVS mediated a noncanonical signal resulting in a prominent increase in mitochondrial ROS levels, and increase in the BACH1/pNRF2 transcription factor ratio and GPX4 up-regulation, which was associated with a 50% decrease in intracellular glutathione levels. We conclude that siRNAs commonly sensitize to ferroptosis and may severely compromise the conclusions drawn from silencing approaches in biomedical research. Finally, as ferroptosis contributes to a variety of pathophysiological processes, we cannot exclude side effects in human siRNA-based therapeutical concepts that should be clinically tested.
Impact Factor
Scopus SNIP
Altmetric
11.700
0.000
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Clinical-pharmacology; Therapeutics; Necrosis; Pathway; Disease; Death; Risk
Language english
Publication Year 2024
HGF-reported in Year 2024
ISSN (print) / ISBN 2375-2548
e-ISSN 2375-2548
Quellenangaben Volume: 10, Issue: 11, Pages: , Article Number: eadk7329 Supplement: ,
Publisher American Association for the Advancement of Science (AAAS)
Publishing Place Washington, DC [u.a.]
Reviewing status Peer reviewed
Institute(s) Institute of Pancreatic Islet Research (IPI)
POF-Topic(s) 90000 - German Center for Diabetes Research
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-502600-007
Grants Cancer Research UK Programme
BMBF (FERROPath consortium)
DFG
International research training group
Heisenberg-Professorship
German Research Foundation
Scopus ID 85188201656
PubMed ID 38489367
Erfassungsdatum 2024-05-07